Repros Therapeutics shares drop on drug application setback

Repros Therapeutics shares tumble in premarket trade after the U.S. FDA said there isn’t enough clinical data to hold a previously-planned pre-investigational new drug application meeting.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.